TY - CHAP M1 - Book, Section TI - Systemic and Topical Antibiotics A1 - Condon, Sean C. A1 - Isada, Carlos M. A1 - Tomecki, Kenneth J. A2 - Kang, Sewon A2 - Amagai, Masayuki A2 - Bruckner, Anna L. A2 - Enk, Alexander H. A2 - Margolis, David J. A2 - McMichael, Amy J. A2 - Orringer, Jeffrey S. PY - 2019 T2 - Fitzpatrick's Dermatology, 9e AB - AT-A-GLANCEEmpiric therapy for skin and soft-tissue infections (SSTIs) is usually successful.β-Lactam antibiotics (penicillins and cephalosporins) and clindamycin are first line options for empiric therapy for mild and moderate nonpurulent SSTIs.Antibiotic resistance is a growing concern. Culture and sensitivity help to define better management.Empiric therapy for moderate and severe purulent SSTIs should cover methicillin-resistant Staphylococcus aureus (MRSA).β-Lactam antibiotics and vancomycin inhibit bacterial cell wall synthesis.Several antibiotic classes interfere with bacterial protein synthesis by binding ribosomal subunits: tetracyclines at 30S; lincosamides (clindamycin), macrolides, streptogramins, and oxazolidinones (linezolid) at 50S.New agents for SSTIs include ceftaroline, lipoglycopeptides (dalbavancin, oritavancin, and telavancin), and oxazolidinones (tedizolid).Topical antibiotics may negate the need for systemic antibiotics in the treatment of impetigo; they are unnecessary as postsurgical prophylaxis to prevent wound infection. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1161343556 ER -